Trade BridgeBio Pharma, Inc. - BBIO CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.14 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023679% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001457% | ||||||||
| Overnight fee time | 21:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 32.96 |
| Open | 32.87 |
| 1-Year Change | 10.01% |
| Day's Range | 32.87 - 34.44 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Apr 1, 2025 | 32.96 | -0.74 | -2.20% | 33.70 | 34.40 | 32.77 |
| Mar 31, 2025 | 34.53 | -0.55 | -1.57% | 35.08 | 35.20 | 33.69 |
| Mar 28, 2025 | 35.03 | -0.87 | -2.42% | 35.90 | 36.05 | 34.90 |
| Mar 27, 2025 | 36.33 | 0.18 | 0.50% | 36.15 | 36.96 | 35.96 |
| Mar 26, 2025 | 36.03 | -0.52 | -1.42% | 36.55 | 36.72 | 35.72 |
| Mar 25, 2025 | 36.70 | -0.26 | -0.70% | 36.96 | 37.49 | 36.40 |
| Mar 24, 2025 | 37.14 | 2.39 | 6.88% | 34.75 | 37.87 | 34.75 |
| Mar 21, 2025 | 34.71 | 1.59 | 4.80% | 33.12 | 34.89 | 32.95 |
| Mar 20, 2025 | 33.86 | 0.89 | 2.70% | 32.97 | 34.49 | 32.95 |
| Mar 19, 2025 | 33.67 | 1.52 | 4.73% | 32.15 | 33.72 | 31.75 |
| Mar 18, 2025 | 32.12 | 0.40 | 1.26% | 31.72 | 32.54 | 31.45 |
| Mar 17, 2025 | 32.95 | 0.10 | 0.30% | 32.85 | 33.37 | 32.23 |
| Mar 14, 2025 | 32.83 | 0.57 | 1.77% | 32.26 | 33.39 | 32.19 |
| Mar 13, 2025 | 32.24 | 0.03 | 0.09% | 32.21 | 32.70 | 31.79 |
| Mar 12, 2025 | 32.52 | 0.21 | 0.65% | 32.31 | 33.10 | 32.31 |
| Mar 11, 2025 | 32.27 | 0.96 | 3.07% | 31.31 | 32.58 | 31.27 |
| Mar 10, 2025 | 31.36 | 0.29 | 0.93% | 31.07 | 31.54 | 30.47 |
| Mar 7, 2025 | 31.52 | -0.45 | -1.41% | 31.97 | 32.55 | 31.16 |
| Mar 6, 2025 | 32.18 | -0.07 | -0.22% | 32.25 | 33.39 | 31.64 |
| Mar 5, 2025 | 34.91 | 1.33 | 3.96% | 33.58 | 35.09 | 33.51 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BridgeBio Pharma, Inc. Company profile
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include BBP-265, a small molecule stabilizer of transthyretin, or TTR, that is in an ongoing Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor which is an ongoing Phase 2 clinical trial for the treatment of achondroplasia in pediatric patients; an AAV5 gene transfer product candidate for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD; and Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, an ongoing phase 2 proof-of-concept clinical trial for Autosomal Dominant Hypocalcemia Type 1, or ADH1. The company also engages in developing products for Mendelian, genetic dermatology, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; The Regents of the University of California; Leidos Biomedical Research, Inc.; the University of California, San Diego; Johns Hopkins University and University of Florida; University of Colorado Anschutz Medical Campus; Salk Institute for Biological Studies; Maze Therapeutics; UC San Francisco; the Canadian Glycomics Network (GlycoNet); the University of California; Columbia University; Mount Sinai; and Helsinn Group, as well as a clinical collaboration with Bristol Myers Squibb to evaluate the combination of BBP-398. It also has a research collaboration and option agreement with Unnatural Products Inc. to target rare diseases with potential oncology applications. The company was founded in 2015 and is headquartered in Palo Alto, California.| Industry: | Biopharmaceuticals |
3160 Porter Dr.
Suite 250
PALO ALTO
CALIFORNIA 94304
US
News
Copper price forecast: third-party price target
What’s next for the copper market? Read on for the latest analysis of the commodity's price and potential outlook.
17:31, 14 March 2025
Coffee price forecast: 2025-2030 third-party coffee target
Coffee prices have cooled considerably in the past few months. Is a rebound in store or will they continue to fall?
09:42, 12 March 2025
The Simpsons predicted XRP to hit $589: Has the show got it right again?
Did the animated TV show predict a breakout for the XRP cryptocurrency?
11:00, 11 March 2025
Rolls-Royce share price forecast: third- party price target
Our Rolls-Royce share price forecast looks at the outlook for the FTSE 100-listed engineering company after a tough few years.
14:58, 10 March 2025
Gasoline petrol price forecast 2025-2030: Third-party price target
Discover third-party gasoline (petrol) price predictions for 2025 and beyond, with analyst targets, historical prices, and trading strategies.
10:27, 3 March 2025
USD forecast - third party data round up
The DXY hit a seven-month low in January, just a few months after a multi-decade peak in late September.
10:02, 27 February 2025
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025People also watch
Still looking for a broker you can trust?
Join the 710,000+ traders worldwide that chose to trade with Capital.com